Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.69 |
| ▸ | SYK | P43405 | 3/20 | 0.49 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8318142 | 0.91 | EGFR (0.68) | EGFRSYKZAP70KCNH2AURKB | |
| SCHEMBL8318904 | 0.90 | EGFR (0.70) | EGFRSYKZAP70KCNH2AURKB | |
| SCHEMBL8316349 | 0.89 | EGFR (0.66) | EGFRSYKZAP70KCNH2AURKB | |
| SCHEMBL8318090 | 0.86 | EGFR (0.77) | EGFRHTTHIF1A | |
| SCHEMBL8315707 | 0.86 | EGFR (0.62) | EGFRSYKZAP70KCNH2AURKB | |
| SCHEMBL8320643 | 0.85 | EGFR (0.72) | EGFRSYKZAP70KCNH2AURKB | |
| SCHEMBL8314771 | 0.85 | EGFR (0.72) | EGFRHTTHIF1A | |
| SCHEMBL8316963 | 0.84 | EGFR (0.86) | EGFRHTTHIF1AERBB2 | |
| SCHEMBL8317938 | 0.84 | EGFR (0.73) | EGFRHTTHIF1A | |
| SCHEMBL8317851 | 0.84 | EGFR (0.77) | EGFRHTTHIF1AERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0779888-B1 | PYRIMIDO [5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-04-28 | — | — | EP | disclosed |